David Seftel, MD, MBA (Harvard)

@DiedSuddenly_ Conclusion This finding actually underscores the importance of staying up-to-date on boosters. People ages 12 and older who have had a bivalent booster shot have a 15 times lower risk of death than an unvaccinated person.

It’s happening. And people are starting to notice. kff.org/policy-watch/w…

I have three more documented cases like this.

Our work at Enable Biosciences in developing one of world's best neutralizing antibody tests for COVID is front page news in many Bay Area Newspapers - mercurynews.com/2021/11/08/is-…

@elandhuis Esther, you were a pioneer in peerless reporting on the this promising prospect! Thank you for your exceptional writing in this regard. Kudos!

Apparently "fluvoxamine for Covid" has become one of my freelance beats

@elandhuis You were a pioneer in peerless reporting on the this promising prospect! Thank you for your exceptional writing in this regard. Kudos!

An absolutely excellent paper, a powerful and persuasive metanalysis and review. Kudos!

@stkirsch I am honored to have you as my first follower Steve!

@DSeftel I am honored to be your very first follower!

My Harvard Business Association of Northern California COVID-19 webinar contributes to a convergence of science and medicine to produce promising news on a therapeutic option for COVID - watch CBS 60 Minutes March 7, 2021 segment: "The Long Shot" - cbsnews.com/news/fluvoxami…

@AbdenurFlavio @stkirsch We are all in it together!

@stkirsch @DSeftel DAMMIT! You beat me to it 😞😒😒

Thanks for all the wonderful feedback on the 60 minutes segment - now Steve Kirsch and I at the COVID Early Treatment Fund (CETF) treatearly.org/need your help to accelerate the further evaluation and parallel use in practice of well qualified repurposed drugs.

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 academic.oup.com/ofid/article/8…